Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) commenced trading on the Hong Kong Stock...
Broncus Medical Acquires Valgen Stake from Venus for $15 Million
Broncus Medical (HKG: 2216) announced that its wholly‑owned subsidiary, Broncus China Holding Corporation, has agreed...
CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that three drug candidates—SYH2072 (aldosterone synthase inhibitor), Priglitin/Dapagliflozin/Metformin...
Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its drug candidate HRS-6257...
Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
Jiangsu Recbio Technology Co., Ltd. (HKG: 2179) announced that the New Drug Application (NDA) for...
Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline
Shenzhen Edge Medical Co., Ltd. (HKG: 2675) has officially listed on the Main Board of...
J&J’s JNJ-5939 Fails Phase 2b Efficacy Endpoint, Triggers Early Termination of Atopic Dermatitis Trial
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Phase 2b DUPLEX‑AD proof‑of‑concept study evaluating JNJ‑95475939...
HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that China’s National Medical Products Administration (NMPA)...
Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
Buchang Pharmaceuticals (SHA: 603858) announced an Exclusive Supply Agreement with Malaysian firm Medispec to register,...
Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in...
Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
Haihe Biopharma Co., Ltd. announced that risovalisib mesylate (CYH33), a highly potent and selective PI3Kα...
Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
Sino Biopharmaceutical Limited (HKG: 1177) announced that TDI01, the world’s first highly selective ROCK2 inhibitor...
TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China
TJ Biopharma (Hangzhou) Co., Ltd. and Jumpcan Holdings Group announced that the Center for Drug...
Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced a licensing agreement with Jiangsu Hengrui Pharmaceutical...
Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
Luye Pharma Group LTD (HKG: 2186) announced that its subsidiary Nanjing Luye, the Divesting Investors,...
Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
Transcenta Holding Limited (HKG: 6628) announced a strategic collaboration and non‑exclusive licensing agreement with EirGenix...
Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its...
BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Shanghai BDgene Technology Co., Ltd. announced that BD920, its in vivo CRISPR gene editing therapy,...
NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories
China’s National Medical Products Administration (NMPA) published the 2025 Edition of the Directory of High-End...
Jenscare Scientific Submits CE Mark Application for JensClip TMVr System in EU
Jenscare Scientific Co., Ltd. (HKG: 9877) announced that it has submitted the registration application for...